- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.03. | Entrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85M | 3 | Seeking Alpha | ||
| 13.03. | Recap: Entrada Therapeutics Q4 Earnings | 1 | Benzinga.com | ||
| 13.03. | Entrada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 13.03. | Entrada Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.03. | Entrada Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Entrada Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.03. | Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results | 834 | GlobeNewswire (Europe) | - Cash runway extended through the second quarter of 2026 - - $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 - - Completed dosing for third cohort of Phase... ► Artikel lesen | |
| 07.03. | Entrada: Strategic Funding Raised From Databricks Ventures | 2 | pulse2.com | ||
| 05.03. | Entrada sichert sich eine strategische Investition von Databricks Ventures, um KI- und Datenkapazitäten zu erweitern | 235 | news aktuell | San Francisco, 5. März 2024 (ots/PRNewswire) - Entrada, ein führendes Databricks-Unternehmen für Beratungs- und Implementierungsdienste, hat eine strategische Investition von Databricks Ventures erhalten... ► Artikel lesen | |
| 04.03. | Entrada Receives Strategic Investment from Databricks Ventures | 1 | FinSMEs | ||
| 04.03. | Entrada AI, Inc.: Entrada Secures Strategic Investment from Databricks Ventures to Scale AI + Data Capabilities | 250 | PR Newswire | SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Entrada, a leading Databricks consulting and implementation services firm, received a strategic investment from Databricks Ventures to help scale... ► Artikel lesen | |
| 07.02. | Entrada Therapeutics, Inc.: Entrada Therapeutics to Present at Upcoming Investor Conferences | - | GlobeNewswire (USA) | ||
| 03.01. | Entrada Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.12.23 | Entrada Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.11.23 | HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know | 1 | Benzinga.com | ||
| 23.11.23 | Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug | 2 | Zacks | ||
| 23.11.23 | Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates | 25 | Zacks | ||
| 22.11.23 | Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? | 1 | Benzinga.com | ||
| 22.11.23 | Entrada falls as FDA keeps muscle-wasting therapy on clinical hold | 1 | Reuters | ||
| 22.11.23 | FDA rebuffs Entrada's attempt to get yearlong hold on DMD drug lifted | 1 | FierceBiotech |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,575 | -3,37 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,045 | +4,50 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,946 | +9,75 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 23,130 | +1,80 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ONCOLYTICS BIOTECH | 1,090 | +1,87 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,025 | +1,49 % | Assertio Holdings Q1 2024 Earnings Preview | ||
| SIGA TECHNOLOGIES | 10,150 | +7,52 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | -0,20 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,390 | +13,18 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,410 | +4,23 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,750 | +3,07 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,610 | -1,88 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 12,330 | +3,35 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
ENTRADA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 13,180 Euro und damit -2,80 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
